Seroquel Sustained-Release Could Avert Sunset On Patent Exclusivity, AstraZeneca Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will file an NDA for the SR formulation of quetiapine for schizophrenia in July.
You may also be interested in...
Seroquel SR NDA Submitted For Schizophrenia
AstraZeneca's once-daily sustained-release formula extends the franchise's patent protection until 2017.
Seroquel SR NDA Submitted For Schizophrenia
AstraZeneca's once-daily sustained-release formula extends the franchise's patent protection until 2017.
AstraZeneca Submits Seroquel sNDA For Bipolar Depression Indication
If approved, Seroquel would be the only agent indicated to treat both depressive and manic episodes associated with bipolar disorder.